Natera (NASDAQ:NTRA) Price Target Raised to $265.00

Natera (NASDAQ:NTRA) had its price target lifted by JPMorgan Chase & Co. from $260.00 to $265.00 in a research report released on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

Other equities analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Robert W. Baird set a $265.00 target price on Natera in a research report on Friday. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a research report on Monday, January 12th. Wall Street Zen upgraded Natera from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, Morgan Stanley cut their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.00.

Natera Stock Performance

Shares of NTRA stock opened at $194.24 on Friday. The stock has a 50 day moving average of $202.23 and a two-hundred day moving average of $215.02. Natera has a 12 month low of $131.81 and a 12 month high of $256.36. The company has a market capitalization of $27.64 billion, a P/E ratio of -119.17 and a beta of 1.57.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 15.72% and a negative net margin of 9.05%.During the same quarter last year, the company earned ($0.41) EPS. Sell-side analysts predict that Natera will post -1.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Natera news, CFO Michael Burkes Brophy sold 3,070 shares of Natera stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total value of $594,781.80. Following the completion of the transaction, the chief financial officer owned 58,291 shares in the company, valued at approximately $11,293,298.34. The trade was a 5.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 1,688 shares of Natera stock in a transaction on Monday, April 27th. The shares were sold at an average price of $204.10, for a total value of $344,520.80. Following the completion of the transaction, the insider owned 187,511 shares of the company’s stock, valued at approximately $38,270,995.10. The trade was a 0.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 38,266 shares of company stock worth $7,747,808. 5.63% of the stock is owned by company insiders.

Hedge Funds Weigh In On Natera

Several institutional investors have recently bought and sold shares of the business. Horizon Investments LLC raised its position in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC increased its stake in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares during the period. Savvy Advisors Inc. raised its position in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after acquiring an additional 47 shares during the last quarter. Finally, First Horizon Corp raised its position in shares of Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after acquiring an additional 51 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: JPMorgan raised its price target on Natera to $265 from $260 and kept an overweight rating, signaling confidence in further upside from current levels. JPMorgan raises Natera price target
• Positive Sentiment: Wells Fargo also lifted its target to $220 from $215, indicating continued analyst support despite a more neutral equal-weight stance. Wells Fargo raises Natera price target
• Positive Sentiment: First-quarter revenue came in well above expectations at $696.6 million, up 38.8% year over year, and the company also reported gross margin of 64.7%, showing strong top-line growth. Natera Q1 results
• Neutral Sentiment: Natera updated full-year 2026 revenue guidance to $2.7 billion-$2.8 billion, roughly in line with consensus, which suggests the outlook is steady but not a major surprise. Natera guidance update
• Negative Sentiment: Profitability remains a concern: Natera posted a quarterly loss of $0.60 per share, wider than the expected $0.53 loss, despite the revenue beat. Natera earnings miss
• Negative Sentiment: Recent insider selling, including a CEO stock sale, may add pressure by reinforcing concerns about valuation after the stock’s strong run. Natera CEO stock sale

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.